• 1
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
  • 2
    Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 2007; 56: 1134-1152.
  • 3
    Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg. 2004; 198: 722-731.
  • 4
    Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995; 221: 721-731; discussion 31-33.
  • 5
    Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006; 4: 766-781; quiz 665.
  • 6
    Schenk M, Schwartz AG, O'Neal E, et al. Familial risk of pancreatic cancer. J Natl Cancer Inst. 2001; 93: 640-644.
  • 7
    Klein AP, Hruban RH, Brune KA, Petersen GM, Goggins M. Familial pancreatic cancer. Cancer J. 2001; 7: 266-273.
  • 8
    Gudlaugsdottir S, van Blankenstein M, Dees J, Wilson JH. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance. Eur J Gastroenterol Hepatol. 2001; 13: 639-645.
  • 9
    Inadomi JM. Surveillance in Barrett's esophagus: a failed premise. Keio J Med. 2009; 58: 12-18.
  • 10
    Yeh JM, Ho W, Hur C. Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival. Gastrointest Endosc. 2010; 72: 33-43.
  • 11
    Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc. 2003; 57: 23-29.
  • 12
    Berthelemy P, Bouisson M, Escourrou J, Vaysse N, Rumeau JL, Pradayrol L. Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med. 1995; 123: 188-191.
  • 13
    Kondo H, Sugano K, Fukayama N, et al. Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. Cancer. 1997; 79: 900-905.
  • 14
    Zou H, Harrington JJ, Taylor WR, et al. Pan-detection of gastrointestinal neoplasms by stool DNA testing: establishment of feasibility. Gastroenterology. 2009; 136: 459-470.
  • 15
    Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 1994; 54: 3568-3573.
  • 16
    Berndt C, Haubold K, Wenger F, et al. K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. Clin Chem. 1998; 44: 2103-2107.
  • 17
    Zou H CX, Domenico M, Harrington J, Taylor W, Yab T, Ahlquist D, Lidgard G. Sensitive quantitation of methylated markers with a novel methylation-specific technology. Presented at: Annual Meeting for the American Association of Clinical Chemistry. July 25-29, 2010; Anaheim, CA.
  • 18
    Ahlquist D, Zou H, Domanico M, Mahoney DW, Thibodeau SN, Lidgard G. Next generation stool DNA testing for detection of colorectal neoplasia—early marker evaluation [abstract]. Presented at: Colorectal Cancer: Biology to Therapy hosted by the American Association for Cancer Research; October 27-30, 2010; Philadelphia PA.
  • 19
    Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004; 351: 2704-2714.
  • 20
    Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008; 149: 441-450, W81.
  • 21
    Omura N, Li CP, Li A, et al. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther. 2008; 7: 1146-1156.
  • 22
    Sato N, Fukushima N, Hruban RH, Goggins M. CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol. 2008; 21: 238-244.
  • 23
    Hong SM, Kelly D, Griffith M, et al. Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol. 2008; 21: 1499-1507.
  • 24
    Matsubayashi H, Canto M, Sato N, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res. 2006; 66: 1208-1217.
  • 25
    Zou H, Harrington JJ, Klatt KK, Ahlquist DA. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1115-1119.
  • 26
    Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998; 17: 857-872.
  • 27
    Hwang C, Kumar S, Yab TC, et al. Noninvasive detection of intraductal papillary mucinous neoplasms (IPMN) and early stage cancer of the pancreas with stool DNA testing. Gastroenterology. 2011; 140( suppl 1): S-678.
  • 28
    Kayed H, Kleeff J, Keleg S, et al. Correlation of glypican-1 expression with TGF-beta, BMP, and activin receptors in pancreatic ductal adenocarcinoma. Int J Oncol. 2006; 29: 1139-1148.
  • 29
    Kleeff J, Maruyama H, Ishiwata T, et al. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology. 1999; 116: 1202-1216.
  • 30
    Hamada S, Satoh K, Hirota M, et al. Bone morphogenetic protein 4 induces epithelial-mesenchymal transition through MSX2 induction on pancreatic cancer cell line. J Cell Physiol. 2007; 213: 768-774.
  • 31
    Hinoue T, Weisenberger DJ, Pan F, et al. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS ONE. 2009; 4: e8357.
  • 32
    Loh K, Chia JA, Greco S, et al. Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. Genes Chromosomes Cancer. 2008; 47: 449-460.
  • 33
    Chen XR, Wang JW, Li X, Zhang H, Ye ZY. Role of BMP3 in progression of gastric carcinoma in Chinese people. World J Gastroenterol. 2010; 16: 1409-1413.
  • 34
    Dai Z, Popkie AP, Zhu WG, et al. Bone morphogenetic protein 3B silencing in non-small-cell lung cancer. Oncogene. 2004; 23: 3521-3529.
  • 35
    Ronneberg JA, Fleischer T, Solvang HK, et al. Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol. 2011; 5: 61-76.
  • 36
    Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 1997; 57: 2140-2143.
  • 37
    Fukushima N, Sato N, Ueki T, et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol. 2002; 160: 1573-1581.
  • 38
    Jansen M, Fukushima N, Rosty C, et al. Aberrant methylation of the 5′ CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol Ther. 2002; 1: 293-296.
  • 39
    Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology. 2001; 121: 640-645.
  • 40
    Chen R, Crispin DA, Pan S, et al. Pilot study of blood biomarker candidates for detection of pancreatic cancer. Pancreas. 2010; 39: 981-988.
  • 41
    Ahlquist DA. Next-generation stool DNA testing: expanding the scope. Gastroenterology. 2009; 136: 2068-2073.
  • 42
    Brune K, Hong SM, Li A, et al. Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev. 2008; 17: 3536-3542.